Skip to main content
User menu
Subscribe
Donate
The HIV Treatment Journal of
Webinars
Current Issue
Drug Guides
Trending
COVID-19 and HIV
HIV Decriminalization
Hepatitis C
U=U
HIV & Aging
HIV Basics
HIV Cure Research
HIV Prevention
HIV Treatment
Stigma & Discrimination
POZ Advocate
Archive
About
Who We Are
Advertise
Contact
Subscribe
Reader/Customer Service
News
Donate
Donate
Bulk Subscriber Donation
Search
HIV Treatment
Back to top
When HIV therapy fails: For treatment-experienced individuals who are experiencing virologic failure
Key considerations and recommendations from the HIV treatment guidelines of the U.S. Department of Health and Human Services (DHHS)
By
May 8, 2022
When HIV therapy fails
Some basic information from U.S. treatment guidelines
By
May 8, 2022
Briefly May+Jun 2022
Cabenuva long-acting injectable no longer requires a month of oral lead-in medication
Enid Vázquez
May 8, 2022
Investigational new drugs
By
Mar 3, 2022
Looking ahead
What’s on the horizon—new drugs in development
Mar 3, 2022
DHHS Recommendations
Guidelines for people starting HIV therapy for the first time
Mar 3, 2022
Contributors
The people behind the 2022 HIV Drug Guide
Mar 3, 2022
FDA approves two-month shot of Cabenuva for HIV
A longer long-acting treatment
By Rick Guasco
Feb 1, 2022
25 years of HAART
The long journey continues
By Michael Broder
Dec 29, 2021
Briefly Jan+Feb 2022
New injectable PrEP given every two months: Apretude
By
Dec 29, 2021
Pagination
Previous page
‹‹
Page 2
Next page
››
Subscribe to HIV Treatment